Cardiology & Heart Surgery - View more

FDA Clears Next-Generation Device to Capture Embolic Debris During TAVR

4 min read
  • The FDA recently cleared Emboliner, a novel embolic protection system that covers the entire aortic arch, helping capture debris before it can travel to the brain or other parts of the body.
  • In a 522-patient global head-to-head trial with another device that provides partial embolic protection, Emboliner demonstrated noninferior 30-day clinical outcomes while capturing more debris.
  • A multidisciplinary team at NewYork-Presbyterian and Columbia pioneered the device’s clinical and commercial use and are exploring how it can be used for other high-risk structural heart procedures where embolic debris is a concern.

A novel device designed to capture and remove embolic debris released during transcatheter aortic valve replacement (TAVR) recently received Food and Drug Administration clearance, providing a new option for patients at risk of injury caused by particles that can travel through the bloodstream to the brain or other vital organs during the procedure.

A multidisciplinary team of interventional cardiologists and cardiac surgeons at NewYork-Presbyterian and Columbia were the first to use the device, known as the Emboliner Embolic Protection System, both in clinical trials and for commercial use. 

“The concept behind the Emboliner is that it provides complete embolic protection by covering the entirety of the aortic arch, including all three vessels to the brain and the descending aorta, in order to capture any debris liberated from the heart before it can cause damage,” says Tamim Nazif, M.D., co-director of the Structural Heart and Valve Center at NewYork-Presbyterian and Columbia and national co-principal investigator of the PROTECT H2H study, which proved the device’s safety and efficacy. “It addresses an unmet need for more comprehensive embolic protection than currently exists for TAVR and other structural heart procedures.”

The novel Emboliner device provides comprehensive protection from debris that can travel to the brain and other parts of the body during TAVR. Image courtesy of Emboline.

The novel Emboliner device provides comprehensive protection from debris that can travel to the brain and other parts of the body during TAVR. Image courtesy of Emboline.

PROTECT H2H Trial Results

The prospective, randomized trial of 522 patients at 20 international sites was a head-to-head comparison between Emboliner and the Sentinel Cerebral Protection System, previously the only option available for providing partial embolic protection. The results, which were presented in a late-breaking session at the 2026 American College of Cardiology Annual Scientific Session and are pending publication, showed Emboliner had noninferior results for 30-day major adverse cardiac and cerebrovascular events (MACCE), including death, stroke, and stage three acute kidney injury. The 30-day MACCE rate was 4.5% for the Emboliner device compared with 5% for Sentinel, while the stroke rate was 2% and 2.1%, respectively. 

Emboliner’s wind-sock-like design, however, allowed it to capture a significantly higher amount of debris. The device is a cylindrical nitinol mesh filter deployed through an existing femoral artery puncture used during TAVR and positioned across the aortic arch through an integrated sheath; the mesh filter allows for debris capture while maintaining blood flow. In the trial, Emboliner captured three times as many clinically significant particles of at least 150 microns and five times the total amount of tissue. The device proved easy to use, with operators being able to successfully place the device in about 96% of cases versus 87% for Sentinel. 

While Sentinel represented an important step forward in improving safety in the earlier days of TAVR, it protects only two of the three blood vessels supplying the brain and provides no protection against debris migrating to the lower body, explains Dr. Nazif, who also participated in early trials of Sentinel. This debris can include dislodged blood clots, endothelium, atherosclerotic plaque, calcified valve tissue, foreign particles, and more.

An example of debris captured during a TAVR procedure.

An example of debris captured during a TAVR procedure.

Many TAVR patients experience subclinical brain injury as a result, with ischemic stroke occurring in about 2% to 4% of patients, Dr. Nazif says. 

“We know there are some populations whose stroke rates are probably higher, such as those with very heavy calcification, bicuspid aortic valves, or those who have bioprosthetic valves and are undergoing a valve-in-valve procedure,” he adds. “What’s exciting about Emboliner is that it provides a safe way to provide protection during TAVR in these higher-risk patients.”

Future Applications and Research

Although the PROTECT H2H trial was not designed to test whether Emboliner lowers stroke rates, “the ultimate hope is that down the road it may be shown to impact stroke,” Dr. Nazif says. 

Testing for that will require a much larger trial of thousands of patients, but the results could help determine whether embolic protection should become a standard of care; currently it is only used in about 10% of TAVR cases, although most patients carry at least some embolic risk. 

In the nearer future, Dr. Nazif believes the technology may offer potential benefits for other structural heart procedures where embolic debris is a concern. “Beyond TAVR, we have a lot of other patients who require higher-risk structural heart procedures — including for the mitral valve, left atrial appendage, or intracardiac thrombus or infection — who could benefit from this new technology,” he says. “We recently published our initial experience with Emboliner in these high embolic risk cases and are planning additional studies on procedures that go beyond the current approval.”

Tamim Nazif, MD
Tamim Nazif, MD

Cardiovascular Disease